Literature DB >> 8713484

HMG-CoA reductase inhibitors: issues in assessing their benefits in coronary heart disease.

A M Gotto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8713484     DOI： 10.2165/00002018-199614010-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  4 in total

Review 1.  Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.

Authors:  T R Pedersen; J A Tobert
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

2.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

3.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

Authors:  M R Law; N J Wald; S G Thompson
Journal:  BMJ       Date:  1994-02-05

4.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.